Future of chemotherapy
作者： M.-O. Grimm , F. H. Hartmann , R. Ackermann
DOI: 10.1007/S00120-006-1055-1
关键词:
摘要: Anhand der erzielten Fortschritte bei Chemotherapie soll die zukunftige Entwicklung abgeleitet werden. Bei Indikationsstellung zur adjuvanten Therapie erfolgt zunehmend eine standardisierte Ermittlung des Rezidivrisikos unter Verwendung aller Prognoseparameter (z. B. Nomogramme). einigen Tumoren ist „molekularer Klassifizerer“, biologischen Eigenschaften eines Tumors anhand molekularer Veranderungen beschreiben, weit fortgeschritten.
springer.com
sci-hub.se 参考文章(24)
Michael W. Kattan, Thomas M. Wheeler, Peter T. Scardino, Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer Journal of Clinical Oncology. ,vol. 17, pp. 1499- 1499 ,(1999) , 10.1200/JCO.1999.17.5.1499
Anne Hamilton, Gabriel Hortobagyi, Chemotherapy: What Progress in the Last 5 Years? Journal of Clinical Oncology. ,vol. 23, pp. 1760- 1775 ,(2005) , 10.1200/JCO.2005.10.034
Bradley C. Leibovich, Michael L. Blute, John C. Cheville, Christine M. Lohse, Igor Frank, Eugene D. Kwon, Amy L. Weaver, Alexander S. Parker, Horst Zincke, Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. ,vol. 97, pp. 1663- 1671 ,(2003) , 10.1002/CNCR.11234
Daniel P. Petrylak, Catherine M. Tangen, Maha H.A. Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna Berry, Carol Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan, E. David Crawford, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer The New England Journal of Medicine. ,vol. 351, pp. 1513- 1520 ,(2004) , 10.1056/NEJMOA041318
David H Johnson, Louis Fehrenbacher, William F Novotny, Roy S Herbst, John J Nemunaitis, David M Jablons, Corey J Langer, Russell F DeVore III, Jacques Gaudreault, Lisa A Damico, Eric Holmgren, Fairooz Kabbinavar, Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 22, pp. 2184- 2191 ,(2004) , 10.1200/JCO.2004.11.022
H. von der Maase, S.W. Hansen, J.T. Roberts, L. Dogliotti, T. Oliver, M.J. Moore, I. Bodrogi, P. Albers, A. Knuth, C.M. Lippert, P. Kerbrat, P. Sanchez Rovira, P. Wersall, S.P. Cleall, D.F. Roychowdhury, I. Tomlin, C.M. Visseren-Grul, P.F. Conte, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology. ,vol. 18, pp. 3068- 3077 ,(2000) , 10.1200/JCO.2000.18.17.3068
Marc L. Citron, Donald A. Berry, Constance Cirrincione, Clifford Hudis, Eric P. Winer, William J. Gradishar, Nancy E. Davidson, Silvana Martino, Robert Livingston, James N. Ingle, Edith A. Perez, John Carpenter, David Hurd, James F. Holland, Barbara L. Smith, Carolyn I. Sartor, Eleanor H. Leung, Jeffrey Abrams, Richard L. Schilsky, Hyman B. Muss, Larry Norton, Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 Journal of Clinical Oncology. ,vol. 21, pp. 1431- 1439 ,(2003) , 10.1200/JCO.2003.09.081
Jeremy M.G. Taylor, Menggang Yu, Howard M. Sandler, Individualized Predictions of Disease Progression Following Radiation Therapy for Prostate Cancer Journal of Clinical Oncology. ,vol. 23, pp. 816- 825 ,(2005) , 10.1200/JCO.2005.12.156
George W. Sledge, What Is Targeted Therapy Journal of Clinical Oncology. ,vol. 23, pp. 1614- 1615 ,(2005) , 10.1200/JCO.2005.01.016
Eisenberger MA Tannock IF1, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, TAX 327 Investigators., None, Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer The New England Journal of Medicine. ,vol. 351, pp. 1502- 1512 ,(2004) , 10.1056/NEJMOA040720